Form 13-F position report

BRAVEHEART BIO INC COM

Reported by ORBIMED ADVISORS LLC

BRVE CUSIP 10567X101 Manager CIK 0001055951

First reported at 12,175,159 shares this quarter.

New
% of reported 13F value 4.49% This manager · Q3 2026
Shares 12,175,159 Quarter-end amount reported
Reported value $245,938,212 Fair value at quarter end
Consecutive quarters held 1 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2026-09-30 245938212

Quarterly position history

How this manager's reported quarter-end position changed over time.

1 quarter
Quarterly reported position history for BRAVEHEART BIO INC COM held by ORBIMED ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 New 12,175,159 +12,175,159 (0.0%) 4.49% $245,938,212 2026-11-16

Who else reported the position

64 managers reported BRAVEHEART BIO INC COM for Q3 2026.

Managers reporting BRAVEHEART BIO INC COM in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FCPM III SERVICES B V New 21,826,024 +21,826,024 41.57% $440,885,685 1 qtr
ORBIMED ADVISORS LLC This report New 12,175,159 +12,175,159 4.49% $245,938,212 1 qtr
AH Capital Management L L C New 10,232,420 +10,232,420 1.04% $206,694,884 1 qtr
FMR LLC New 7,585,769 +7,585,769 < 0.01% $153,232,533 1 qtr
Frazier Life Sciences Management L P New 5,267,321 +5,267,321 2.64% $106,399,884 1 qtr
Enavate Sciences GP LLC New 3,674,656 +3,674,656 26.53% $74,228,051 1 qtr
Capital International Investors New 1,300,000 +1,300,000 < 0.01% $26,260,000 1 qtr
Avoro Capital Advisors LLC New 1,255,000 +1,255,000 0.26% $25,351,000 1 qtr
Capital Research Global Investors New 1,034,097 +1,034,097 < 0.01% $20,888,759 1 qtr
BlackRock Inc New 1,007,129 +1,007,129 < 0.01% $20,344,007 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM SHS

Voting authority reported

Sole
12,175,159
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.